Blog >


Umbrex is pleased to welcome Maria Chevtsova. Maria spent five years in the Boston, New York, and Moscow offices of BCG working on strategic and operational projects with increasing focus on the Healthcare/BioPharma space. She transitioned into industry as an Inhouse Consultant at Merck KGaA and most recently built out and lead Portfolio Strategy and […]

Umbrex is pleased to welcome Miguel Guarino. Miguel, spent 4 years at McKinsey after completing the Masters in Management. Previously a lawyer, from 2004 to 2010. Miguel describes his practice: After my years at McKinsey I joined Finsolutia, leading the Advisory and Portfolio Management teams, where I contributed to growing AuM from 300m€ to 1.6b€ […]

Umbrex is pleased to welcome Chintan Dhanji.  Chintan is a seasoned consultant that has worked strategy consulting with Bain & Co and independently since 2014 where he has worked across the value chain to enhance organization profitability and market share in the telecoms, technology, financial services, healthcare, FMCG and agri-business industries. Prior to this, he […]

Sindhu Kutty shares an article that explores the No Surprises Act introduced in January of this year and offers a few suggestions that could improve it. As a business owner, and one with more than 20 years of experience in the healthcare space, I know that maneuvering through the outrageous complexity of the provider and […]

Umbrex is pleased to welcome Robert K Armstrong with Epicural.  Bob Armstrong has 15+ years experience consulting to startups, DoD, PE firms, established healthcare market leaders, state and federal government, and Fortune 500 companies. He provides corporate outreach for, and is executive director of the Sentara Center for Simulation and Immersive Learning at Eastern Virginia Medical […]

Jim Price shares a whitepaper he co-authored with Abby Coleman, and Haley Teves on the 340B-eligible health system.  This paper explores how a 340B-eligible health system can leverage its control of its own health plan to lower its net drug benefit costs by increasing the compliant-usage of 340B (which generates margin by the Covered Entity […]

Umbrex is pleased to welcome Karen Zwiebel. Karen is a seasoned professional with over 20 years of experience as a strategy consultant and business executive. While working at McKinsey & Company and as an Independent Professional, she has helped clients define, develop, grow and optimize their businesses. As an executive at several international banks, she […]


Andrew McKee shares an article on the latest developments in Ulcerative Colitis.  Many of our clients are pursuing groundbreaking therapies in disease areas with high unmet medical needs, giving our firm the chance to become intimately familiar with some of the most exciting areas in drug development.  One disease area that is receiving a lot […]

Umbrex is pleased to welcome David Madukauwa-David.  David, previously a generalist at BCG, recently kicked off his own consulting firm focused on corporate strategy/M&A in healthcare. Prior to BCG, he was an engineer and researcher, working at Georgia Tech, IFSTTAR, CEA, and Airbus among others. David has deep expertise in new product development within medical […]

Umbrex is pleased to welcome Ashish Vatsal with Vatsal Consulting Group.  Ashish is an independent consultant interested in combining strategy, implementation, and data for values-driven organizations that recognize financial return is just one dimension of success. He most recently spent eight years as a Managing Consulting, Owner, and Account Leader at Point B and started […]